The era of the #computable human is here! 🚀 Join @nference at the 1st Bio-X Convergence this Monday, June 16 at the Hyatt Place in Boston / Seaport. Be part of a historic moment and witness the launch of #TheComputableHumanProject. Learn more: nference.com/events/bio-x-co… #HealthTech #AIAgents #Boston #AgenticAI

Registration & Speakers: nference.com/bio-x-convergen…

Thrilled to share what we've been working on -- The Computable Human Project. Join @_nference at The 1st BIO-X Convergence on June 16th (Monday) at The Hyatt Place in the Boston Seaport area to learn more: nference.com/bio-x-convergen… @geochurch Robert Langer @HirzelAlan @AmiBhattMD @CMichaelGibson Shivkumar Kalyanam MD PhD Harlan Krumholz MD Reza Vagefi MD Jean-Paul Chretien MD PhD Andy Danielsen @vabgoel Vijay Shah MD Chidebelu Ufodike Ye Bu @manoliskellis PhD Enrique García-Rivera PhD Anne Carpenter PhD @JF_PetitNivard Cliff Rosen MD Shailesh Agarwal MD Mone Zaidi MD Jay G. Ronquillo, MD, Matt Lynes MD Venkat Thiruvallur @ShiraDoronMD @michaelmina_lab MD PhD Emir Roach, MD Jane Urban Craig Tendler MD Manish Kohli PhD Husseini Manji, MD, FRCPC Aatif Husain Sadhna Kohli Georgia Papathomas Andrew Fleming Jason Maron, MBA AJ Venkatakrishnan PhD @MattHurchik Aaron Mathias Brian Urban MBA Murali Aravamudan #BIO #BIO2025 #patientsfirst #TheFutureIsHere #TheFutureIsNow #TheFutureIsYou #AI #AgenticAI #AIAgents #GenerativeAI #GenAI #AIforGood #ScienceWillWin

nference was named one of the 50 best healthcare #DataAnalytics companies in the US, per @Newsweek. Thank you to @BeckersHR for highlighting the recognition: beckershospitalreview.com/di… Request a demo of our AI software platform: nference.com/demo #RealWorldEvidence #AI

nference is honored to be recognized as one of the World’s Best #DigitalHealth Companies in 2024 by @Newsweek. Request a demo of our #AI software platform that is transforming healthcare by making biomedical data computable: nference.com/demo newsweek.com/rankings/worlds…

Research led by nference and @MadrigalPharma underscores the capacity of the Fibrosis-4 (FIB-4) index to forecast not only liver decompensation, but also cardiovascular events in patients with #NASH. The study highlights that a FIB-4 score as low as 1.0 can indicate significant risk for #cardiovascular events. This finding is in contrast to current guidelines which stratify FIB-4 scores less than 1.3 as low risk and scores up to 2.67 as intermediate risk. This potentially groundbreaking insight for NASH treatment was made possible by the nference AI platform, providing unparalleled access to longitudinal #patientdata from the world’s top medical centers. Leveraging nference cutting-edge language models, researchers are able to rapidly identify patients for their study populations with greater accuracy. Download the poster: images.prismic.io/nference/Z… Request a demo of the nference AI platform: nference.com/demo #Fibrosis #Liver #LanguageModels #PatientIdentification

nference language models are able to identify disease warning signs earlier than health care professionals. With our Augmented Curation #AI technology, physicians and researchers can analyze disease signs and symptoms from unstructured clinical text at scale. AL amyloidosis is an excellent example for the value of #AugmentedCuration, as it is frequently misdiagnosed due to its signs and symptoms often mimicking more-common diseases. Also know as primary #amyloidosis, this life-threatening disease results from an abnormality of plasma cells in the bone marrow and while closely related to multiple myeloma, treatment options are far less prevalent. nference collaborated with @JNJInnovMed and the @MayoClinic to study the accuracy of Augmented Curation on over 1,200 AL amyloidosis patients. Our findings demonstrate that the language model-based method matches the quality of manual curation, while being significantly more time-efficient and cost-effective. Going forward, a language model-based method for identifying signs and symptoms from clinical notes could be integrated as part of an AL amyloidosis screening or #EarlyIdentification tool. These tools could reduce the time from the initial presentation of AL amyloidosis to treatment of the disease. Read the peer-reviewed study: doi.org/10.1002/ajh.27019 Request a demo of our AI platform: nference.com/demo #LanguageModels #DiseaseDetection #RealWorldEvidence

Anumana’s algorithms are #inthenews today! On the #TodayShow, @drpaulfriedman, chair of Anumana's Scientific Advisory board explains how ECG-AI can detect #heartdisease earlier. Excited to work with the amazing team at #MayoClinic to supercharge ECGs and improve patient outcomes!

Through advances in data science, multimodal real-world data (#RWD) is becoming an essential tool for drug developers to identify the most appropriate patients to enroll in clinical trials. With our federated AI platform, #nSights, pharma leaders gain access to millions of longitudinal patient lives across the leading medical institutions, including @MayoClinic and @DukeHealth. With this multimodal data, linked to individual patient records, researchers can rapidly compare the impact of different inclusion and exclusion criteria on patient cohorts and clinical outcomes. Learn more about the nSights platform: nference.com/nsights Request an nSights Demo: nference.com/nsights-demo-fo… #clinicaltrials #drugdevelopment #rwe #federatedlearning #ai

If you're at @PMWCintl, come hear our VP of Scientific Research and Partnerships Dr. AJ Venkatakrishnan speak about reimagining biomedicine in the age of AI. #FederatedAI #RWE #AI #DataAnalytics #healthcaredata #PMWC2024

We're excited to speak at @PMWCintl next week in Silicon Valley! If you're at the event, make sure to attend VP of Scientific Research & Partnerships AJ Venkatakrishnan's talk on reimagining biomedicine in the age of AI. #FederatedAI #AI #DataAnalytics #healthcaredata #PMWC2024

Our federated data network provides access to de-identified patient data from top medical centers. nSights enables access as if it were on a single platform for a seamless experience. Learn more about how nSights can help you: nference.com/nsights

ICYMI: CAP TODAY shared a roundup of several of Pramana's exciting new collaborations with Caris Life Sciences, Intermountain Health, Gestalt Diagnostics, and Techcyte. Stay tuned for more exciting news in 2024! Read the article: captodayonline.com/newsbytes…

Embrace the future of healthcare with data-driven insights from nference's #FederatedAI. Transform patient care, predict outbreaks, personalize treatments, and more. Explore use cases at nference.com/nsights.

In case you missed it, the @DukeHealth #OneDukeGen initiative with nference to advance one of the largest clinical genomics sequencing and interpretation efforts was featured in Precision Medicine Online! 📰 lnkd.in/e3pPV8Su #FederatedAI

Unlock the profound world of healthcare insights with our #FederatedAI. Dive deep into patient progression, therapy indicators, and disease nuances. Discover the future of healthcare at nference.com

How do federated data networks enhance R&D? By connecting diverse data sources, we can access #RWE insights from multiple institutions-fueling innovative drug development & evidence-based decisions. Learn how our #FederatedAI solves #realworldproblems nference.com/pharma

In case you missed it, @CLPmag recently reshared a podcast episode with nference and Pramana Chief Product Officer Prasanth Perugupalli. Listen to the podcast: bit.ly/3Qaa9KP

What is the final barrier to the digital pathology revolution? Pramana Medical Director Asa Rubin tackles this question in The Pathologist, explaining how to overcome obstacles, foster community, and pave the way for the future of digital pathology. bit.ly/3uF6M6d